AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38848522
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine
Trial: 35978334
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components (motivational counseling, nicotine replacement patches/lozenges, message framing)
Trial: 35978334
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components
Trial: 34906386
Drug: Autologous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fat grafting (AFG) protocol with a single injection of autologous fat grafting and dressed with nano fat (Group A)
Trial: 34906386
Drug: Conventional methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional methods of serial dressings with 1% silver sulphadiazine or other topical agents (Group B)
Trial: 34529000
Drug: Neoadjuvant paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant paclitaxel plus investigational agents (graduated treatments)
Trial: 34529000
Drug: Neoadjuvant paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant paclitaxel plus investigational agents (non-graduated treatments)
Trial: 34529000
Drug: Neoadjuvant paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant paclitaxel plus chemotherapy alone (control)
Trial: 33515745
Drug: Gore-Tex suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gore-Tex suture (2-0 Gore-Tex; W. L. Gore & Associates, Inc.)
Trial: 32759543
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA)
Trial: 32759543
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with 2.5 mg/day rosuvastatin
Trial: 32812652
Drug: PIEB +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB + PCEA (5 ml bolus every hour, 5 ml PCEA bolus lockout 20 minutes)
Trial: 32812652
Drug: CEI +
RxNorm normalized name: Ceiba pentandra fiber
DrugBank: Ceiba pentandra fiber (DB10411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI + PCEA (5 ml/h, 5 ml PCEA bolus, lockout 20 minutes)
Trial: 33772508
Drug: Ketogenic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic diet (KD) therapy
Trial: 33772508
Drug: Control (adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (adjustment of antiepileptic drugs)
Trial: 35472141
Drug: Preoperative denosumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative denosumab, curettage and adjuvant local therapy (Arm B)
Trial: 35472141
Drug: Curettage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curettage and adjuvant local therapy (Arm A)
Trial: 32155315
Drug: Deutetrabenazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (25 mg)
Trial: 32155315
Drug: Tetrabenazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (25 mg)
Trial: 34427633
Drug: Ontamalimab 75
RxNorm normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontamalimab 75 mg every 4 weeks
Trial: 32240350
Drug: 50% low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% low-dose images
Trial: 32240350
Drug: Standard-dose images
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose images
Trial: 32240350
Drug: Low-dose images
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose images
Trial: 35491524
Drug: Exenatide twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice-daily 10 μg with dapagliflozin-matched placebo
Trial: 32046931
Drug: MET‐LIRA (MET-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET‐LIRA (MET-2000 mg, LIRA 1.8 mg SC QD)
Trial: 32046931
Drug: MET‐P (MET-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET‐P (MET-2000 mg, Placebo QD)
Trial: 35405248
Drug: Metformin (METF)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (METF) for 2 weeks
Trial: 34050768
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole (POS) prophylaxis for 7 days
Trial: 34167827
Drug: 200-mg CTC
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg CTC (equivalent to 112-mg celecoxib and 88-mg tramadol)
Trial: 34167827
Drug: 100-mg tramadol
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg tramadol
Trial: 34167827
Drug: 100-mg celecoxib
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg celecoxib
Trial: 34167827
Drug: 100-mg celecoxib
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg celecoxib plus 100-mg tramadol
Trial: 32744106
Drug: Anti-PD-1/PD-L1-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1-based therapy
Trial: 34551104
Drug: Ad5-vectored COVID-19
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored COVID-19 vaccine (5 × 10^10 viral particles)
Trial: 34551104
Drug: Ad5-vectored COVID-19
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored COVID-19 vaccine (single dose)
Trial: 33979802
Drug: Pedometer-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer-based intervention with weekly goals
Trial: 32801651
Drug: JPI-289 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 35 mg
Trial: 32801651
Drug: JPI-289 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 75 mg
Trial: 32801651
Drug: JPI-289 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 150 mg
Trial: 32801651
Drug: JPI-289 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 300 mg
Trial: 32801651
Drug: JPI-289 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 450 mg
Trial: 32801651
Drug: JPI-289 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 600 mg
Trial: 32402554
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment (overall)
Trial: 32615110
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m2) with carboplatin AUC5 or AUC6 every 3 weeks (group 2)
Trial: 32615110
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m2) with carboplatin AUC2 weekly (group 3)
Trial: 32615110
Drug: 3-weekly chemotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-weekly chemotherapy (carboplatin AUC5 or AUC6 and 175 mg/m2 intravenous paclitaxel) (group 1)
Trial: 33888772
Drug: linagliptin/metformin 2.5/850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin/metformin 2.5/850 mg twice daily (LM group)
Trial: 33888772
Drug: metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 850 mg twice daily (M group)
Trial: 33308425
Drug: Cabotegravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir plus rilpivirine long‐acting every 8 weeks (cabotegravir 600 mg plus rilpivirine 900 mg)
Trial: 33308425
Drug: Cabotegravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir plus rilpivirine long‐acting every 4 weeks (cabotegravir 400 mg plus rilpivirine 600 mg)
Trial: 35773357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tadalafil 5 mg and Silodosin 8 mg
Trial: 34177933
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with pembrolizumab
Trial: 34177933
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiotherapy and immunotherapy
Trial: 32880094
Drug: Tailored work-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored work-related support intervention (3 psychosocial meetings before treatment)
Trial: 36244652
Drug: High-dose losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose losartan (150 mg/d)
Trial: 36244652
Drug: Low-dose losartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose losartan (50 mg/d)
Trial: 33419660
Drug: Treatment Initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Initiation Program
Trial: 35659791
Drug: Ultraviolet-C (UV-C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet-C (UV-C) light treatment with a room decontamination device
Trial: 32453759
Drug: dezocine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezocine (1 mg/kg) with sufentanil (1.3 μg/kg)
Trial: 32453759
Drug: sufentanil (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil (2.3 μg/kg)
Trial: 35987809
Drug: Nutritional supplements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements, protein‐rich, high‐fiber diet, care by a professional nutritionist
Trial: 39037762
Drug: Preoperative statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative statin therapy
Trial: 36075592
Drug: Calcitriol soft
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol soft capsules (0.25 μg each time, twice a day for 12 weeks).
Trial: 33878192
Drug: Transdermal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal CO2 gel
Trial: 33878192
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (ultrasound gel)
Trial: 36202236
Drug: COVID‐19 Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID‐19 Vaccine Message
Trial: 34479797
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation (400-1600 IU/d)
Trial: 35510562
Drug: Treatment (vaccine)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (vaccine)
Trial: 35742279
Drug: Online group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online group (n = 19) - 40‐min trunk stabilization exercise sessions twice a week for six weeks via ZOOM
Trial: 34110614
Drug: 25 1-mg
RxNorm normalized name: Folplex 2.2 MG / 1 MG / 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 1-mg OM slow-release minitablets
Trial: 34110614
Drug: 25 1-mg
RxNorm normalized name: Folplex 2.2 MG / 1 MG / 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 1-mg OM fast-release minitablets
Trial: 34110614
Drug: 25-mg OM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-mg OM matrix MR tablet
Trial: 34237987
Drug: Traditional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatments (non-surgical group)
Trial: 32867832
Drug: Parent Child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent Child Interaction Therapy ‐ Toddler
Trial: 32556730
Drug: Haemoblock (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoblock (15 ml retromuscularly and 15 ml subcutaneously)
Trial: 35518935
Drug: Hydrocortisone dose
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone dose of 0.2-0.3 mg/kg/day
Trial: 35518935
Drug: Hydrocortisone dose
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone dose of 0.4-0.6 mg/kg/day
Trial: 34732432
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy (62 patients)
Trial: 34732432
Drug: Non-anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anticoagulation treatment (446 patients)
Trial: 34732432
Drug: Preoperative anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative anticoagulation therapy
Trial: 35189937
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) consisting of 14 teleconference sessions with the child and parents, supported by an app for symptom assessment and wristband monitoring.
Trial: 35189937
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group receiving treatment after a 16-week waiting period.
Trial: 34076179
Drug: 25% oral
RxNorm normalized name: glucose 25% oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% oral glucose
Trial: 34076179
Drug: 25% oral
RxNorm normalized name: glucose 25% oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% oral glucose combined with non-nutritive sucking
Trial: 34196852
Drug: Povidone-iodine irrigation
RxNorm normalized name: povidone-iodine Irrigation Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine irrigation of oral cavity for 3 min before operation
Trial: 34196852
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate irrigation of oral cavity for 3 min before operation
Trial: 33512412
Drug: Response-adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with involved-field radiation therapy (RT)
Trial: 33512412
Drug: Response-adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide without involved-field radiation therapy (RT)
Trial: 33512412
Drug: Additional chemotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional chemotherapy with dexamethasone, etoposide, cisplatin, and cytarabine for patients with slow early response
Trial: 34990581
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban regimen (HDER) 60 mg/reduced 30 mg
Trial: 34990581
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban regimen (LDER) 30 mg/reduced 15 mg
Trial: 35221703
Drug: Bilastine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine (standard dose)
Trial: 35221703
Drug: Fexofenadine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (standard dose)
Trial: 35221703
Drug: Levocetirizine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (standard dose)
Trial: 35221703
Drug: Bilastine (up-dosing)
RxNorm normalized name: Q-Up
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bilastine (up-dosing)
Trial: 35221703
Drug: Fexofenadine (up-dosing)
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine (up-dosing)
Trial: 35221703
Drug: Levocetirizine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine + Hydroxyzine (combination)
Trial: 33954789
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid (ZA) with calcium and vitamin D; 5 infusions (0.025 mg/kg at months 0 and 3, 0.05 mg/kg at months 6, 12, and 18)
Trial: 34970330
Drug: Aerosolized glucocorticoid
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized glucocorticoid combined with bronchodilator
Trial: 36278221
Drug: H2-O2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-O2 group (inhaled H2-O2 mixture 66% H2/33% O2)
Trial: 36278221
Drug: Air group
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air group (inhaled placebo air)
Trial: 36334697
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D administration
Trial: 32046418
Drug: Single-dose secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose secnidazole 2 g
Trial: 34055971
Drug: Nomogram based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram based on predictive variables (age, site, grade, tumor size, histology, stage, use of surgery, radiotherapy, or chemotherapy)
Trial: 33422811
Drug: Non-metformin users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-metformin users
Trial: 36320143
Drug: Low-dose temsirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose temsirolimus (0.1 mg/mL)
Trial: 36320143
Drug: High-dose temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose temsirolimus (0.4 mg/mL)
Trial: 36320143
Drug: Temsirolimus (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (combined low and high dose)
Trial: 35470243
Drug: G‐POEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐POEM
Trial: 34688948
Drug: T-cell receptor
RxNorm normalized name: T-cell receptor marker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell receptor beta chain (TCRβ) features in COVID-19 patients
Trial: 36401364
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich gel (APRG)
Trial: 33598778
Drug: 0.8% hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% hyaluronic acid gel + open flap debridement (OFD)
Trial: 32176093
Drug: Pharyngeal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharyngeal electrical stimulation (PES) treatment on 3 consecutive days in addition to best supportive care
Trial: 32176093
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment on 3 consecutive days in addition to best supportive care
Trial: 32585837
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate + bioactives (WPI + BIO) capsules containing omega‐3 fatty acids, rutin, and curcumin
Trial: 32585837
Drug: Carbohydrate +
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate + placebo capsules (CHO)
Trial: 35671100
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy (ILIT) with ALK Alutard Birch and Grass 1000 SQ‐U, three intralymphatic injections with one-month intervals
Trial: 33979488
Drug: Tezepelumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (210 mg) every 4 weeks for 52 weeks
Trial: 33979488
Drug: Tezepelumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (210 mg)
Trial: 34813673
Drug: Cenobamate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (200 mg/day, median modal dose)
Trial: 34813673
Drug: Cenobamate (≥100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (≥100 mg/day)
Trial: 32445670
Drug: Subcutaneous C1‐INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous C1‐INH (40 IU/kg or 60 IU/kg) administered twice weekly for 52 to 140 weeks
Trial: 36075589
Drug: Xingnao Kaiqiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnao Kaiqiao acupuncture in addition to rt-PA intravenous thrombolysis
Trial: 36075589
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (rt-PA intravenous thrombolysis only)
Trial: 33284201
Drug: Early commencement
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early commencement of parenteral nutrition immediately after birth
Trial: 33284201
Drug: Commencement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commencement of parenteral nutrition within 24 hours of admission